Ruconest

DRUG3 trials

Sponsors

Pharming Technologies B.V., IMMUNOe Research Centers, Bernstein Clinical Research Center

Conditions

Confirmed Coronavirus DiseaseCovid19Hereditary AngioedemaPost-Viral Disorder (Disorder)Post-Viral Fatigue Syndrome

Phase 2

Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

CompletedNCT04530136

Pharming Technologies B.V.Confirmed Coronavirus Disease

Start: 2020-11-30End: 2021-12-01Updated: 2024-02-16

Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

CompletedNCT04705831

IMMUNOe Research CentersCovid19, Post-Viral Disorder (Disorder), Post-Viral Fatigue Syndrome

Start: 2021-01-11End: 2024-07-01Updated: 2025-08-11

Phase 4

Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)

CompletedNCT06690047

Bernstein Clinical Research CenterHereditary Angioedema

Start: 2018-08-14End: 2022-04-28Updated: 2024-11-15

Related Papers

Does C1 esterase inhibitor play a role in post COVID-19 neurological symptoms? A randomized, double-blind, placebo-controlled, crossover, proof-of-concept study.

2025-11-06